TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3324594

Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic prophylaxis (1 dose preoperatively)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Short-term antibiotic prophylaxis (1 dose preoperatively and 2 doses postoperatively)
Number of subjects: 564
Study: 29883259

Group type: EXPERIMENTAL
Intervention: Ligament balancing
Number of subjects: 129

Group type: COMPARATOR
Intervention: Non-ligament balancing
Number of subjects: 129
Study: 26349433

Group type: EXPERIMENTAL
Intervention: Tonsillectomy with steroid pulse therapy (TSP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Steroid pulse monotherapy
Number of subjects: 59
Study: 25320699

Group type: EXPERIMENTAL
Intervention: Pharyngeal pack
Number of subjects: 140

Group type: COMPARATOR
Intervention: No pharyngeal pack (control)
Number of subjects: 140
Study: 22547304

Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma (PRP) applied before sternal wiring, n = 97
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group, n = 99
Number of subjects: 196
Study: 19687468

Group type: EXPERIMENTAL
Intervention: HEROS PLUS Coping Skills Training (CST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-person long-term follow-up plus telephone-delivered psychosocial care
Number of subjects: 0
Study: 18254767

Group type: EXPERIMENTAL
Intervention: Ultrasound pretreatment plus 2-minute low-voltage iontophoresis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard, 10-minute high-voltage iontophoresis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham-ultrasound plus 2-minute low-voltage iontophoresis
Number of subjects: 30
Study: 16603033

Group type: EXPERIMENTAL
Intervention: Neutral state in OCD patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Symptom provoked state in OCD patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Path analysis in OCD patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 12
Study: 12755659

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 635

Group type: COMPARATOR
Intervention: Presence of Axis II personality disorder comorbidity
Number of subjects: 635
Study: 11015147

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Nucleoside analogue regimens (ZDV, didanosine (ddI), ZDV + ddI, ZDV + zalcitabine (ddC))
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Nucleoside analogue therapy
Number of subjects: 2467
Study: 8991356

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Moduretic
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 9
Study: 7958380

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral ketorolac (10 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ketogan (standard regimen)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 100
Study: 3113357

Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Verapamil 480 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 31422858

Group type: EXPERIMENTAL
Intervention: Modified Valsalva maneuver
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Valsalva maneuver
Number of subjects: 0
Study: 29729530

Group type: EXPERIMENTAL
Intervention: Multiple viewings of UV facial photo
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Single viewing of UV facial photo
Number of subjects: 151

Group type: COMPARATOR
Intervention: No viewing of UV facial photo (Control)
Number of subjects: 151
Study: 27880086

Group type: EXPERIMENTAL
Intervention: Calendula officinalis vaginal cream
Number of subjects: 150

Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 150
Study: 24508849

Group type: EXPERIMENTAL
Intervention: Instruction leaflets for measuring child's weight and height
Number of subjects: 164

Group type: COMPARATOR
Intervention: Simple estimated parental reports
Number of subjects: 164
Study: 22089378

Group type: EXPERIMENTAL
Intervention: etravirine in combination with darunavir/ritonavir
Number of subjects: 0
Study: 19389246

Group type: EXPERIMENTAL
Intervention: Cognitive‐behaviour therapy (10 weekly sessions)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Recommended pharmacological treatment (pregabalin 300‐600 mg/day, with duloxetine 60‐120 mg/day if comorbid depression)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual treatment at primary care level
Number of subjects: 180
Study: 17244133

Group type: EXPERIMENTAL
Intervention: Oral health visit (OHV) invitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 15837982

Group type: EXPERIMENTAL
Intervention: AC-DOC (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 21 days followed by docetaxel 100 mg/m2 every 21 days for four cycles)
Number of subjects: 913

Group type: COMPARATOR
Intervention: ADOC (doxorubicin 50 mg/m2 plus docetaxel 75 mg/m2 every 14 days for four cycles with filgrastim support)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: AC-DOC
Number of subjects: 913
Study: 11995345

Group type: EXPERIMENTAL
Intervention: Walking into the operating room (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Being carried on a stretcher (n = 30)
Number of subjects: 60
Study: 9562927

Group type: EXPERIMENTAL
Intervention: Heparin therapy
Number of subjects: 199
Study: 7836705

Group type: EXPERIMENTAL
Intervention: Thymopentin therapy for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 3343428

Group type: EXPERIMENTAL
Intervention: Non-protected lower respiratory tract secretions (LRS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Protected specimen brushes (PSB)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bacteriological count
Number of subjects: 24
Study: 30076979

Group type: EXPERIMENTAL
Intervention: Five-biomarker signature in training set (N=330)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Five-biomarker signature in validation set C (N=318)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Five-biomarker signature in validation set S (N=126)
Number of subjects: 330
Study: 27196574

Group type: EXPERIMENTAL
Intervention: ibodutant 10 mg
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: ibodutant 1 mg, 3 mg, 10 mg
Number of subjects: 559

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: ibodutant (all doses)
Number of subjects: 559
Study: 26135376

Group type: EXPERIMENTAL
Intervention: Multimodal exercise training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tai Chi
Number of subjects: 40
Study: 23810109

Group type: EXPERIMENTAL
Intervention: Low-volume, energy- and nutrient-dense oral nutritional supplement (ONS) 2 × 125 mL (600 kcal, 24 g protein) per day
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (CG) receiving routine care
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low-volume, energy- and nutrient-dense ONS
Number of subjects: 77
Study: 21421296

Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO) diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Almond diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Common background diet (control for all diets)
Number of subjects: 18
Study: 18346647

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 17154786

Group type: EXPERIMENTAL
Intervention: tau-dot hypothesis of braking control
Number of subjects: 0

Group type: COMPARATOR
Intervention: direct estimation and control of ideal deceleration
Number of subjects: 0
Study: 13130390

Group type: EXPERIMENTAL
Intervention: EGb 761®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11078132

Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Wire fixation
Number of subjects: 127
Study: 8814584

Group type: EXPERIMENTAL
Intervention: Digital subtraction radiography (DSR)
Number of subjects: 17
Study: 1334792

Group type: EXPERIMENTAL
Intervention: Nicardipine (Perdipine)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nifedipine (Towarat)
Number of subjects: 37
Study: 6363156

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 105

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study: 31735729

Group type: EXPERIMENTAL
Intervention: AC-OCT
Number of subjects: 400

Group type: COMPARATOR
Intervention: C-OCT
Number of subjects: 400
Study: 29887127

Group type: EXPERIMENTAL
Intervention: Mutuality Scale (MS) for heart failure patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mutuality Scale (MS) for caregivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mutuality Scale (MS)
Number of subjects: 0
Study: 28005767

Group type: EXPERIMENTAL
Intervention: New bioresorbable osteosynthesis materials
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard titanium miniplates
Number of subjects: 12
Study: 25104835

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive-behavioural therapy (CBT) for 12 weeks
Number of subjects: 158

Group type: COMPARATOR
Intervention: Behavioural stress management (BSM) for 12 weeks
Number of subjects: 158
Study: 22302459

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 40
Study: 20362457

Group type: EXPERIMENTAL
Intervention: No Touch (NT) technique
Number of subjects: 91
Study: 17284861

Group type: EXPERIMENTAL
Intervention: CSNs10 (10 mg/kg of capsinoids)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CSNs3 (3 mg/kg of capsinoids)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 44
Study: 16214915

Group type: COMPARATOR
Intervention: Mail
Number of subjects: 145467

Group type: COMPARATOR
Intervention: Mail Plus Incentive
Number of subjects: 145467

Group type: COMPARATOR
Intervention: Control
Number of subjects: 145467
Study: 12399272

Group type: EXPERIMENTAL
Intervention: 4 g EPA/d for 6 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 4 g DHA/d for 6 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 59
Study: 10410487

Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 179
Study: 7595709

Group type: EXPERIMENTAL
Intervention: Paclitaxel via 3-hour infusion at a starting dose of 250 mg/m2 for group I and 175 mg/m2 for group II.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Paclitaxel via 3-hour infusion without prophylactic G-CSF.
Number of subjects: 49
Study: 2150166

Group type: EXPERIMENTAL
Intervention: Nicorandil (10(-4) M)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Time-matched control (n = 5)
Number of subjects: 11
Study: 7027924

Group type: EXPERIMENTAL
Intervention: Cefoxitin (1-g preoperative bolus)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cephalothin (1-g preoperative dose)
Number of subjects: 48
Study: 31353222

Group type: EXPERIMENTAL
Intervention: Human connectome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Macaque connectome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primitive organisms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human connectome Laplacian matrix
Number of subjects: 0
Study: 27911471

Group type: EXPERIMENTAL
Intervention: 100 mg CoQ10 supplements per day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27447107

Group type: EXPERIMENTAL
Intervention: Ethyl alcohol-based sanitizer
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride-based sanitizer
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Soap-and-water handwashing
Number of subjects: 95
Study: 24142232

Group type: EXPERIMENTAL
Intervention: M72/AS01B (40 μg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: M72/AS01E (10 μg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: M72/AS01E (20 μg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: M72/AS02D (10 μg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: M72/Saline (40 μg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: AS01B alone
Number of subjects: 6
Study: 22052267

Group type: EXPERIMENTAL
Intervention: 0.1% hyaluronan formulations of different molecular weights (50, 130, 300, 800 and 2000 kDa) applied twice-daily for 60 days
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 0.1% hyaluronan formulations (specifically 130 and 50 kDa)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Vehicle control cream applied to the other eye
Number of subjects: 76
Study: 19347867

Group type: EXPERIMENTAL
Intervention: COX-2-587Arg variant
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: 1759A allele presence
Number of subjects: 1026
Study: 16679433

Group type: EXPERIMENTAL
Intervention: Immediate treatment with disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Delayed start with disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Fast radiographic progression during the first year and first 2 years
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 482
Study: 15531933

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin and 25 mg of rofecoxib
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11125853

Group type: EXPERIMENTAL
Intervention: Higher total aggression and attitudinal hostility scores on the BDHI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal population
Number of subjects: 0
Study: 9323747

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral HIV risk reduction group intervention with advocacy training (7 sessions)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral HIV risk reduction group intervention (7 sessions)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Single AIDS education session
Number of subjects: 104
Study: 8400345

Group type: EXPERIMENTAL
Intervention: MPA/PVP formulation (200 mg sachet)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard formulation (500 mg tablet)
Number of subjects: 26
Study: 3461726

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/butalbital 50 mg/caffeine 40 mg/codeine 30 mg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Acetaminophen 300 mg/codeine 30 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 31061718

Group type: EXPERIMENTAL
Intervention: Augmented Depression Therapy (ADepT) - 15 weekly acute sessions and 5 booster sessions in the following year
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT) - 20 weekly acute sessions
Number of subjects: 80
Study: 29024304

Group type: EXPERIMENTAL
Intervention: Alprostadil (20 ug/day, intravenous administration diluted with 100 ml normal saline, from 0.5 to 1 hr before to 3 days after operation)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (hydration therapy only)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 480
Study: 27097833

Group type: EXPERIMENTAL
Intervention: Home-based progressive resistance training (PRT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 49
Study: 24857532

Group type: EXPERIMENTAL
Intervention: Resilience training (eight 90-minute sessions)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (eight 90-minute sessions)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3
Study: 22661182

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 μg/kg 1 min before administration of fentanyl 2 μg/kg (Group II)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Fentanyl 2.5 μg/kg (Group I)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 μg/kg 1 min before administration of fentanyl 1.5 μg/kg (Group III)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 μg/kg 1 min before administration of fentanyl 1 μg/kg (Group IV)
Number of subjects: 400
Study: 20714709

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17692643

Group type: EXPERIMENTAL
Intervention: Continuous fenoldopam infusion (0.06 mcg/kg per minute)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 40
Study: 15866625

Group type: EXPERIMENTAL
Intervention: cyclosporine or tacrolimus with secondary immunosuppression including mycophenolate match (MMF) or azathioprine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: azathioprine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: delayed graft function
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: acute rejection episodes
Number of subjects: 20

Group type: COMPARATOR
Intervention: not applicable
Number of subjects: 20
Study: 12553675

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 24
Study: 9598780

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 500 mg
Number of subjects: 12
Study: 7636773

Group type: EXPERIMENTAL
Intervention: Collaborative-based intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional, staff-directed intervention
Number of subjects: 80
Study: 2651332

Group type: EXPERIMENTAL
Intervention: 3 g/day of Tisacid (acid‐neutralizing capacity = 78 mmol)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 6 g/day of Tisacid (acid‐neutralizing capacity = 156 mmol)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 12 g/day of Tisacid (acid‐neutralizing capacity = 312 mmol)
Number of subjects: 332

Group type: COMPARATOR
Intervention: 1.0 g/day cimetidine (control)
Number of subjects: 332
Study: 138654

Group type: EXPERIMENTAL
Intervention: Terracortril ointment or cream
Number of subjects: 85
Study: 30545717

Group type: EXPERIMENTAL
Intervention: Chloroquine as weekly chemoprophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine as intermittent treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28624580

Group type: EXPERIMENTAL
Intervention: PPI (pantoprazole 40 mg/day)
Number of subjects: 30
Study: 24732671

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 200 μg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 100 μg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 183
Study: 24021303

Group type: EXPERIMENTAL
Intervention: CJ‐50300 smallpox vaccine administered with a bifurcated needle over the deltoid muscle.
Number of subjects: 145
Study: 21721072

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Weekly assessment
Number of subjects: 90
Study: 19555036

Group type: EXPERIMENTAL
Intervention: Nebivolol (5.0 mg/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ivabradin (mean dose 7.5 mg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Basic combined therapy (ACE inhibitors, diuretics, aspirin, statins, on demand nitrates)
Number of subjects: 92
Study: 16290998

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12127368

Group type: EXPERIMENTAL
Intervention: Phase Plane (PP) ECG analysis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard ECG analysis
Number of subjects: 18
Study: 10187933

Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray (group II)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lidocaine infiltrative anesthesia (group III)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No anesthesia (group I)
Number of subjects: 75
Study: 8800725

Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution (group II, n = 100)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Stanford solution (group I, n = 95)
Number of subjects: 195
Study: 2146389

Group type: EXPERIMENTAL
Intervention: Direct trocar insertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verres needle use
Number of subjects: 0
Study: 313148

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Crossover from medical to surgical therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 74

Group type: COMPARATOR
Intervention: Predictors of total inpatient cost
Number of subjects: 74
Study: 31324199

Group type: EXPERIMENTAL
Intervention: Sanjin tablets plus levofloxacin tablets placebo
Number of subjects: 252

Group type: COMPARATOR
Intervention: Levofloxacin tablets plus Sanjin tablets placebo
Number of subjects: 252

Group type: COMPARATOR
Intervention: Sanjin tablets plus levofloxacin tablets
Number of subjects: 252
Study: 28467145

Group type: EXPERIMENTAL
Intervention: ACP‐I Plan intervention (includes emotional support and systems navigation)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 74